Cyrus Harmon
Can fully shutting down the estrogen receptor make a difference in breast cancer? Olema scores $54M to find out in the clinic
From tamoxifen to aromatase inhibitors to fulvestrant, there’s been no lack of endocrine treatments targeted at estrogen receptor-positive breast cancer. But Olema Oncology believes there …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
